| NCT ID | NCT06861673 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Asklepios proresearch |
| Condition | Atrial Fibrillation (AF) |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-03-01 |
| Primary Completion | 2026-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2025-03-01 with a primary completion date of 2026-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In patients with non-valvular AF, at high stroke risk, and who are ineligible for long-term oral anticoagulation LAAC could be an alternative to anticoagulation and safety and efficacy has been shown in several studies and registries.8 While PVI and LAAC are both conducted in the left atrium and share the same access route, a combined concomitant approach might be beneficial for patients but is not conventionally practiced. Due to significantly shorter procedures times and high safety profile PFA based catheter ablation may be advantageous for the combined approach of PVI and LAAC. We are performing a word-wide, retrospective, multicenter registry study focusing on patients with concomitant Farapulse PFA based PVI and LAAC (WATCHMAN Flx, Boston Scientific). To evaluate safety, efficacy and efficiency in a multicenter study the COCONUT study was conducted.
Eligibility Criteria
Inclusion Criteria: Indicatio for PVI and LAAC Exclusion Criteria: Not eligible for any of the procedures PVI and LAAC
Frequently Asked Questions
Who can join the NCT06861673 clinical trial?
This trial is open to participants of all sexes, studying Atrial Fibrillation (AF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06861673 currently recruiting?
Yes, NCT06861673 is actively recruiting participants. Visit ClinicalTrials.gov or contact Asklepios proresearch to inquire about joining.
Where is the NCT06861673 trial being conducted?
This trial is being conducted at Hamburg, Germany.
Who is sponsoring the NCT06861673 clinical trial?
NCT06861673 is sponsored by Asklepios proresearch. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.